Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ā„12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and previous ...
GlaxoSmithKline plc (GSK) today announced results from the 'LABA' (long acting beta 2-agonist) safety study, AUSTRI(SAS115359). The study compared Advair ® Diskus ®, a combination of the LABA, ...
Advair 250/50 Now the Only Treatment Approved to Both Reduce Exacerbations and Improve Lung Function RESEARCH TRIANGLE PARK, N.C., May 1 -- Late yesterday the U.S. Food and Drug Administration ...
The FDA has warned healthcare professionals and consumers not to use certain Advair Diskus (fluticasone propionate and salmeterol inhalation powder, from GlaxoSmithKline) inhalers stolen from a ...
The Food and Drug Administration has accepted Lannettās abbreviated new drug application for fluticasone propionate and salmeterol inhalation powder in three strengths ā a generic of GlaxoSmithKline's ...
SILVER SPRING, Md., July 16 /PRNewswire-USNewswire/ -- The FDA is warning the public that certain Advair Diskus inhalers stolen from a distribution warehouse in 2009 have been found in some pharmacies ...
LONDON, Dec. 17, 2020 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has received FDA approval for and launched its generic version of ...
Dec. 8, 2004 -- The U.S. Food and Drug Administration (FDA) approved in September revisions to safety labeling to advise healthcare professionals of the following changes: discontinuation of ...
The FDA also expanded the use of Advair Diskus 250/50 to a broader patient population which includes not only patients with COPD associated with chronic bronchitis, but also emphysema or both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results